نتایج جستجو برای: tositumomab

تعداد نتایج: 347  

2012
Margarita Maurer Rajasekharan Somasundaram Meenhard Herlyn Stephan N. Wagner

Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 ...

Journal: :Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2013
Haifeng Zhang Liping Song Hongtu Ye Lide Hu Wenlu Liang Datao Liu

BACKGROUND Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%. Also, immunogenicity was reported in 17-20% patients receiving the treatment, making it unsuitable for long term diseases such as autoimmune disorders. It has been a hot resea...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2002
Rosana B Michel M Jules Mattes

In previous experiments, 125I-labeled 1F5 (anti-CD20)was found to kill B-lymphoma cells efficiently and specifically.Unexpectedly, the number of antibody (Ab) molecules taken up per cell was much larger than the number of antigen sites on the cell surface. The present studies were designed to explain this apparent discrepancy. Incubation with fluorophore-conjugated 1F5, using the Raji cell line...

Journal: :Blood 2008
Rosa Lapalombella Bo Yu Georgia Triantafillou Qing Liu Jonathan P Butchar Gerard Lozanski Asha Ramanunni Lisa L Smith William Blum Leslie Andritsos Da-Sheng Wang Amy Lehman Ching-Shih Chen Amy J Johnson Guido Marcucci Robert J Lee L James Lee Susheela Tridandapani Natarajan Muthusamy John C Byrd

Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investigated as a therapy for chronic lymphocytic leukemia (CLL). The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide. We therefore examined whether lenalidomide combined with rituximab enhances direct apoptosis and ...

2017
R. Suárez-Fernández Gregorio Marañón

3. Thatayatikom A, White AJ. Rituximab: A promising therapy in systemic lupus erythematosus. Autoimmun Rev. 2006;5:18--24. 4. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520--35. 5. Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24:553--63. 6. Fatourechi MM, el-...

Journal: :Cancer biotherapy & radiopharmaceuticals 2006
Manuel J Koppe Wim J G Oyen Robert P Bleichrodt Albert A Verhofstad David M Goldenberg Otto C Boerman

INTRODUCTION Gemcitabine has been shown to exert a radiosensitizing effect in various epithelial cancers. The aim of the present studies was to investigate whether the efficacy of radioimmunotherapy (RIT) using the (131)I-labeled anti-CEA monoclonal antibody (MAb) MN-14 could be enhanced by coadministration of gemcitabine in nude mice with small (1-3 mm) peritoneal metastases of colonic origin....

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1996
C T Kuan I Pastan

B1(dsFv)-PE33 is a recombinant immunotoxin composed of a mutant form of Pseudomonas exotoxin (PE) that does not need proteolytic activation and a disulfide-stabilized Fv fragment of the anti-Lewis(y) monoclonal antibody B1, which recognizes a carbohydrate epitope on human carcinoma cells. In this molecule, amino acids 1-279 of PE are deleted and domain Ib (amino acids 365-394) is replaced by th...

Journal: :Infection and immunity 2015
Waleed Elsegeiny Taylor Eddens Kong Chen Jay K Kolls

Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patient...

Journal: :Frontiers in bioscience 2011
Alfredo Amoroso Sameh Hafsi Loredana Militello Alessia E Russo Zohra Soua Maria C Mazzarino Franca Stivala Massimo Libra

The addition of anti-CD20 monoclonal antibody (rituximab) to chemotherapy has significantly improved survival in B-cell lymphoma. However, a substantial number of patients relapse after treatment with rituximab. Understanding of anti-CD20 antibody molecular function may facilitate the development of pharmacologic strategies to overcome resistance. Cell death have been demonstrated to be caused ...

2015
Lukáš Smolej

Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید